Elvitegravir clinical trials
Also written GS-9137.
Counted the way a researcher would: Elvitegravir with its salts, dosage forms, brands and biosimilars. Looking for a trial to join? Including related medicines shows more you could take part in.
This browser remembers your choice.
How each study uses elvitegravir is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the elvitegravir studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 27 Aug 2012 · STRIBILD · NDA 203100 (FDA, Drugs@FDA; in a combination)
- European Union
- 24 May 2013 · Stribild · EMEA/H/C/002574 (EMA; in a combination)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
27 studies that test it; most in 2013 (7)
| Year | Studies |
|---|---|
| 2006 | 1 |
| 2007 | 1 |
| 2008 | 1 |
| 2011 | 1 |
| 2012 | 1 |
| 2013 | 7 |
| 2014 | 3 |
| 2015 | 7 |
| 2016 | 2 |
| 2017 | 1 |
| 2018 | 1 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 22 · Other 5
Gilead Sciences (21) · Janssen Sciences Ireland UC (1) · Technical University of Munich (1) · Fundacion Clinic per a la Recerca Biomédica (1) · St Stephens Aids Trust (1) · Juan A. Arnaiz (1) · Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic (1)
Often tested with
Tested in the same studies.
Cobicistat (23) · Emtricitabine (21) · Tenofovir alafenamide (20) · Darunavir (3) · Bictegravir (2) · Atazanavir (2) · Emtricitabine/Rilpivirine/Tenofovir Alafenamide Fumarate (2) · Emtricitabine tenofovir alafenamide (2)
Related medicines
As reviewed, each with the page that says it.
- One of Integrase inhibitors source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test elvitegravir.
Studies
Open first, then newest update. How each study uses elvitegravir is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 27
- A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV TreatmentsRecruitingPhase 4Gilead SciencesNCT06337032Written as E/C/F/TAFHow we know
- Study to Evaluate the Pharmacokinetics, Safety, and Antiviral Activity of the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Single Tablet Regimen (STR) in HIV-1 Infected Antiretroviral Treatment-Naive Adolescents and Virologically Suppressed ChildrenCompletedPhase 2/3Gilead SciencesNCT01854775Written as E/C/F/TAFHow we know
- Cost-effectiveness of Different Antiretroviral Treatment in Patients HIV NaiveWithdrawnPhase 4Juan A. ArnaizNCT02470650Written as elvitegravir/cobicistat/emtricitabine/tenofovirHow we know
- Study to Evaluate Switching From a TDF-Containing Combination Regimen to a TAF-Containing Fixed Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Positive ParticipantsCompletedPhase 3Gilead SciencesNCT01815736Written as E/C/F/TAFHow we know
- Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of E/C/F/TAF Fixed Dose Combination (FDC) in HIV-1 Infected Adults on Chronic HemodialysisCompletedPhase 3Gilead SciencesNCT02600819Written as E/C/F/TAFHow we know
- Study to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) in Virologically-Suppressed HIV-1 Infected Adults Harboring the Archived Isolated NRTI Resistance Mutation M184V/M184ICompletedPhase 3Gilead SciencesNCT02616029Written as E/C/F/TAFHow we know
- Same-Day Treatment With Genvoya vs. EFV/TDF/3TCWithdrawnNot applicableHaitian Group for the Study of Kaposi's Sarcoma and OpportunisticNCT03405194Written as Elvitegravir, Cobicistat, TAF, FTCHow we know
- Safety and Efficacy of Switching to a FDC of B/F/TAF From E/C/F/TAF, E/C/F/TDF, or ATV+RTV+FTC/TDF in Virologically Suppressed HIV-1 Infected WomenCompletedPhase 3Gilead SciencesNCT02652624Written as E/C/F/TAFHow we know
- Switching From a Tenofovir Disoproxil Fumarate (TDF) Containing Regimen to Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Alafenamide (E/C/F/TAF) Fixed-Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Infected Adults Aged ≥ 60 YearsCompletedPhase 3Gilead SciencesNCT02616783Written as E/C/F/TAFHow we know
- Open-label Safety Study of E/C/F/TAF (Genvoya®) in HIV-1 Positive Patients With Mild to Moderate Renal ImpairmentCompletedPhase 3Gilead SciencesNCT01818596Written as E/C/F/TAFHow we know
- Study to Evaluate the Safety and Efficacy of E/C/F/TAF Versus E/C/F/TDF in HIV-1 Positive, Antiretroviral Treatment-Naive AdultsCompletedPhase 3Gilead SciencesNCT01797445Written as E/C/F/TAFHow we know
- Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected AdolescentsCompletedPhase 2/3Gilead SciencesNCT02276612Written as E/C/F/TAFHow we know
- Safety and Efficacy of E/C/F/TAF (Genvoya®) Versus E/C/F/TDF (Stribild®) in HIV-1 Infected, Antiretroviral Treatment-Naive AdultsCompletedPhase 2Gilead SciencesNCT01497899Written as E/C/F/TAFHow we know
- Study to Evaluate the Safety and Efficacy of E/C/F/TAF (Genvoya®) Versus E/C/F/TDF (Stribild®) in HIV-1 Positive, Antiretroviral Treatment-Naive AdultsCompletedPhase 3Gilead SciencesNCT01780506Written as E/C/F/TAFHow we know
- Efficacy and Safety of E/C/F/TAF (Genvoya®) in HIV-1/Hepatitis B Co-infected AdultsCompletedPhase 3Gilead SciencesNCT02071082Written as E/C/F/TAFHow we know
- Efficacy of Tenofovir Alafenamide Versus Placebo Added to a Failing Regimen Followed by Treatment With Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Atazanavir in HIV-1 Positive, Antiretroviral Treatment-Experienced AdultsCompletedPhase 3Gilead SciencesNCT01967940Written as E/C/F/TAFHow we know
- Phase 3 Open-Label Study to Evaluate Switching From Optimized Stable Antiretroviral Regimens Containing Darunavir to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) Plus Darunavir (DRV) in Treatment Experienced HIV-1 Positive AdultsCompletedPhase 3Gilead SciencesNCT01968551Written as E/C/F/TAFHow we know
- Efficacy, Safety, and Tolerability of Ledipasvir/Sofosbuvir (LDV/SOF) Treatment for HIV/HCV Co-infected Participants Who Switch to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) or Emtricitabine/Rilpivirine/Tenofovir Alafenamide (F/R/TAF) Prior to LDV/SOF HCV TreatmentCompletedPhase 3Gilead SciencesNCT02707601Written as E/C/F/TAFHow we know
- Safety and Efficacy of Switching From Regimens of ABC/3TC + a 3rd Agent to E/C/F/TAF Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV 1 Infected AdultsCompletedPhase 3Gilead SciencesNCT02605954Written as E/C/F/TAFHow we know
- Two Part Study to Evaluate Pharmacokinetics, Safety, and Antiviral Activity of Elvitegravir Administered With a PI/r Background Regimen for ARV Treatment-Experienced Pediatric ParticipantsTerminatedPhase 2/3Gilead SciencesNCT01923311Written as EVGHow we know
See all 27 studies that test elvitegravir →
Given beside what is tested · 1 — elvitegravir is usual care or a partner of the new treatment
Codes
What other systems call elvitegravir · ClinicalTrials.gg INT004902
- MeSH (NLM) C509700elvitegravirConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 4GDQ854U53ELVITEGRAVIRConfirmed FDA, NLM, Wikidata
- RxNorm 1306286Confirmed FDA, Wikidata
- Wikidata Q2740966elvitegravirConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C76493ElvitegravirOne source FDA
- DrugBank DB09101One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C509700 | elvitegravir | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 4GDQ854U53 | ELVITEGRAVIR | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1306286 | — | Confirmed FDA, Wikidata |
| Wikidata | Q2740966 | elvitegravir | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C76493 | Elvitegravir | One source FDA |
| DrugBank | DB09101 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.